Comparison
Matrixyl vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
214047-00-4
2023788-19-2
Molecular weight
802.06 g/mol
4813 g/mol
Half-life
no data
116 h
Sequence
Palmitoyl-Lys-Thr-Thr-Lys-SerYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
3
of which in humans
2
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2